Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.43 |
| ▸ | GRM5 | P41594 | 5/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 3/20 | 0.34 |
| ▸ | FNTB | P49356 | 3/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274895 | 0.90 | MET (0.44) | METGRM5NQO2GABRG2GABRB3 | |
| SCHEMBL256018 | 0.86 | TP53 (0.35) | METNQO2 | |
| SCHEMBL13274649 | 0.82 | MET (0.45) | METGRM5NQO2ALKBH1 | |
| SCHEMBL173429 | 0.82 | BRD4 (0.34) | METNQO2 | |
| SCHEMBL2221042 | 0.81 | MET (0.41) | METNQO2ALKBH1FNTAFNTB | |
| SCHEMBL2268200 | 0.81 | MET (0.40) | METNQO2ALKBH1FNTAFNTB | |
| SCHEMBL13275105 | 0.80 | MET (0.46) | METGRM5NQO2ALKBH1 | |
| SCHEMBL13275648 | 0.80 | MET (0.40) | METNQO2ALKBH1FNTAFNTB | |
| SCHEMBL13275034 | 0.80 | ALKBH1 (0.43) | METGRM5NQO2GABRG2GABRB3 | |
| SCHEMBL2351533 | 0.80 | MET (0.39) | METGRM5NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | claimed |
| EP-2611450-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| WO-2012030633-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MET, ABL1, ERBB2 | MET 1/4885GRM5 1037/4885NQO2 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.